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Identification of Phenylphthalazinones as a New Class of
Leishmania infantum Inhibitors
Maarten Sijm,[a] Erik de Heuvel,[a] An Matheeussen,[b] Guy Caljon,[b] Louis Maes,[b]
Geert-Jan Sterk,[a] Iwan J. P. de Esch,[a] and Rob Leurs*[a]
Leishmaniasis is a neglected parasitic disease caused by over 20
different Leishmania species. Current treatments often rely on
harsh regimes of pentavalent antimonials such as sodium
stibogluconate, while more recent drugs suffer other short-
comings such as low stability and rapid emergence of treatment
failure, amongst others. Furthermore, the effectiveness of drugs
varies depending on the infecting Leishmania species, thus
there is an urgent need for new and effective anti-leishmanial
drugs. Screening of an in-house compound library identified
the hexahydrophthalazinone NPD-2942 as a low micromolar hit
with a pIC50 of 5.8 against L. infantum and a pIC50 of 4.6 for
cytotoxicity against human MRC-5 fibroblasts. To derive
structure–activity relationships, we modified the cyclohexyl ring
of the hexahydrophthalazinone scaffold and 1,2,3-triazoles were
attempted as replacement for the pyrazole ring, amongst
others. Ultimately, the 2,3-pyrazole-substituted hexahydroph-
thalazinone NPD-1289 was identified as the most potent
analogue in this series with a pIC50 of 6.3, although some
cytotoxicity toward MRC-5 cells (pIC50 =5.1) was recorded as
well. Replacement of the unsubstituted 2,3-pyrazole with 1,2,3-
triazoles led to compounds with lower anti-leishmanial activity.
The current scaffold is a valuable new starting point for
optimization toward novel anti-leishmanial drugs.
Introduction
Leishmaniasis is a neglected parasitic disease which comes in
several distinct clinical manifestations and is caused by over 20
different Leishmania species which are transmitted by phlebot-
omine sand flies.[1] Visceral leishmaniasis (VL) is caused by L.
donovani and L. infantum, with 500.000 new infections annually
resulting in 50.000 deaths, although this number could be
higher due to underreporting.[2] Estimations are that another 1.5
million people are suffering from cutaneous leishmaniasis (CL),
which is caused by almost all other Leishmania species.[3]
For 70 years the standard treatment of leishmaniasis is with
pentavalent antimonials meglumine antimonate (1) and sodium
stibogluconate (2) (Figure 1).[4,5] While quite effective outside
the Indian subcontinent, the treatment regimens of 3 daily
injections for 30 days, often accompanied with severe pains, are
far from ideal.[3,6] Furthermore, treatment is relatively expensive
and often requires additional medical supervision as a result of
side effects such as vomiting, cardiotoxicity and
hepatotoxicity.[7] Due to different effectiveness of antimonials
against the various Leishmania species and emerging drug
resistance, amphotericin B (3) is currently recommended as
first-line treatment.[2,3,8] Some patients however suffer from
infusion reactions like chills and fever, while serious toxicity has
been reported as well.[9] As such, much research has been
directed toward improved formulations of amphotericin B (3) to
enhance drug delivery and reduce toxicity.[9]
Due to the high cost and low stability of amphotericin B (3),
pentavalent antimonials are still commonly used in rural areas
where a cold chain is absent. Other newly introduced drugs
also have serious concerns. The phospholipid miltefosine (4) is
the first oral drug available against leishmaniasis, initially
showing high cure rates of 95 % with only minor side effects.[10]
However, more recent reports from the clinic indicate sub-
stantial levels of treatment failure.[11–13] The aminoglycoside
paromomycin (5) shows cure rates up to 85 % with a treatment
regime for a 35 kg person costing less than 5 euro.[14,15] The
largest downside of paromomycin is the relatively long treat-
ment regime of injections for 21 days. Experimental resistance
selection also showed a high propensity for resistance develop-
ment when used in monotherapy.[16] Combination treatments
with sodium stibogluconate (2) improve the effectiveness for VL
to cure rates of ~ 93 %.[17]
The last decades several drugs have been added to the
toolbox against leishmaniasis, although each drug has its
limitations.[14] Furthermore, there is a large interspecies difference
of drug susceptibility and each clinical form of leishmaniasis has
different requirements toward the pharmacokinetics of a drug.
Hence, there remains an urgent need for new therapeutics.
To identify new hits against Leishmania, an in-house
compound library was screened against Leishmania infantum.
The majority of compounds in this library were previously
obtained from other anti-parasitic programs. From this screen-
ing, hexahydrophthalazinone (6) was identified as a hit with a
pIC50 of 5.8 against L. infantum and low toxicity against human
MRC-5 cells. To investigate the structure-activity relationships
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(SAR) for this potential new chemical class of antiparasitic drugs,
the cyclohexane part of the hexahydrophthalazinone, the
phthalazinone-N-substituent and the aromatic substituent of
the anisole ring were selected for modification.
Chemistry
The first step of the synthesis of hexahydrophthalazinone
analogues was the Friedel-Crafts acylation of 2-bromoanisole with
several anhydrides, yielding the corresponding keto-acids (9–10,
12, Scheme 1). The keto-acid precursor (11) for tetrahydrophthala-
zinone was prepared in two steps; first a Friedel-Crafts acylation
was done with maleic anhydride leading to trans-keto-acid 8,
which was followed by a Diels-Alder reaction with 1,3-butadiene
resulting in trans-keto-acid 11. Ring-closure of these keto-acids
with hydrazine yielded the desired hexahydrophthalazinone (13),
dihydropyridazinone (14), tetrahydrophthalazinone (15) and
phthalazinone (16). An isopropyl moiety was installed on the
unsubstituted phthalazinones and pyridazone using sodium
hydride and isopropylbromide (17–20). In case of tetrahydroph-
thalazinone (11) the alkylation reaction with NaH resulted in the
conversion of the trans-isomer to the cis-isomer as previously
reported by de Heuvel et al.[15] After the alkylation the final
aromatic substituents could be introduced via a Suzuki cross-
coupling resulting in analogues substituted with various pyrazoles
(21–23, 26–32), 2-furan (24) and 3-tiophene (25).
Further differentiation of the substituents on the hexahy-
drophthalazinone nitrogen (Scheme 2), was done by deproto-
nation with sodium hydride followed by addition of the desired
alkyl halides (33–36). On the alkylated intermediates the so far
most promising 4-1H-pyrazolone was installed using a Suzuki
cross-coupling (37–41).
Introduction of the 1,2,3-triazoles was done starting with
isopropyl hexahydrophthalazinone 18 (Scheme 3), which was
used in a Sonogashira reaction with trimetylsilylacetylene to
yield 42. The TMS protecting group (42) was removed with
potassium hydroxide in MeOH, resulting in the acetylene
substituted building-block (43). The desired azides were
prepared in situ by refluxing sodium azide with the desired alkyl
halide in MeOH/H2O (8 : 1).
[16] After 16 hours this mixture was
cooled to room temperature and a portion of the azide solution
was added to a mixture of the acetylene building block (43),
CuSO4 and l-ascorbate, yielding the desired 1,2,3-triazoles (44–
51) after stirring overnight at room temperature.
Figure 1. Pentavalent antimony drugs meglumine antiomonate (1), sodium stibogluconate (2), amphotericin B (3), miltefosine (4), paromomycin (5), and
identified hit NPD-2942 (6).
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The first series of analogues synthesized around hit molecule
NPD-2942 (6, Figure 1) had modifications at two distinct
positions. By modifying R1 and R2, the role of the hexyl ring of
the hexahydrophthalazinone scaffold was investigated, while
modifications on R3 were introduced to investigate the SAR of
the hetero-aromatic substituent (Table 1). Introduction of a
Scheme 1. Synthesis of various phthalazinones and pyridazinones: a) AlCl3, anhydride, CH2Cl2, RT, 16 h, 58–78 %, b) buta-1,3-diene, THF, 140 °C, 30 min, 10 bar,
97 %. c) N2H4.H2O, EtOH, RT–60 °C, 16 h, 20–89 %, d) isopropyl bromide, NaH, DMF, 50 °C, RT, 81–90 %, e) R3-B(OH)2 or R3-pinacol, Na2CO3, Pd(dppf)Cl2·CH2Cl2,
H2O/DME (1 : 3), 120 °C, 1 h, 8–26 %.
Scheme 2. Synthesis of hexahydrophthalazinones: a) alkyl bromide or chloride, NaH, DMF, 50 °C, RT, 57–92 %, b) pyrazole-B(OH)2, Na2CO3, Pd(dppf)Cl2·CH2Cl2,
H2O/DME (1 : 3), 120 °C, 1 h, 14–29 %.
Full Papers
221ChemMedChem 2020, 15, 219 – 227 www.chemmedchem.org © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Freitag, 17.01.2020


























































methyl group on the 1,2-pyrazole (21) reduced antiparasitic
activity to 5.1 (pIC50). Instead, installation of a 2,3-pyrazole ring,
either unsubstituted (22) or methylated (23), improved activity
compared to the original hit (6), with both compounds showing
pIC50 values of 6.3. Cytotoxicity toward human MRC-5 cells was
however higher for the methylated analogue (23, pIC50 =5.6,
SI=5) than the unsubstituted pyrazole (22, pIC50 =5.1, SI=16).
Introduction of other heterocyclic rings, such as a 2-furan (24)
and 3-thiophene ring (25) resulted in compounds with
decreased activities (pIC50 values around 5.1). The removal of
the cyclohexene ring (26–27) resulted in pIC50 values of 4.5,
which is a decrease of 1.3 log units compared to original hit
NPD-2942 (6). This shows the importance of having a
cyclohexane ring on this position. Introduction of a cyclohexene
ring instead of a cyclohexane, as in compounds 28–30, resulted
in a small increase in activity compared to the original hit (6) for
the unsubstituted 1,2-pyrazole (28) with a pIC50 of 6.0. However,
MRC-5 cytotoxicity of 28 also increased with 0.3 log unit
showing 13 fold selectivity toward L. inf. The unsubstituted 2,3-
pyrazole (29) had similar potency as the original hit (6) (pIC50 =
5.7) while the methylated analogue (30), was more potent with
a pIC50 of 6.3. This increased potency of 30 was however
accompanied with an increase of MRC-5 toxicity (pIC50 =5.4).
Replacing the cyclohexane ring with a phenyl moiety is
tolerated, as 2,3-pyrazoles 31 and 32 showed pIC50 values of 5.6
and 6.0 respectively for the unsubstituted and methylated
analogues. Both compounds, however, also showed some MRC-
5 cytotoxicity with pIC50 values around 5.0.
After this first round of SAR, it was decided to continue with
the unsubstituted 2,3-pyrazole on the R3 position and a
cyclohexene ring on R1 and R2. This compound, NPD-1289 (22),
which has 16 fold selectivity over human cells with a pIC50 of
6.3 and a MRC-5 cytotoxicity of 5.1 (pIC50), showed the best
selectivity index in this series. The next position which was
investigated for optimization was the substituent of the
phthalazinone nitrogen (R4, Table 2).
Removal of the isopropyl moiety led to compound 37,
which was considered inactive (pIC50 =4.2) against L. infantum
but did show substantial cytotoxicity toward MRC-5 cells
(pIC50 =5.5). Installation of a cyclobutylmethyl instead of the
isopropyl moiety of 22 resulted in analogue 38. This molecule
shows low micromolar activity against L. infantum (pIC50 =5.9),
but is accompanied with substantial cytotoxicity (pIC50 =5.6).
The three cyclopropyl-2-oxoethyl 39, benzyl 40 and 4-
pyridinylmethyl 41 analogues all showed even higher cytotox-
icity for MRC-5 cells compared to their activities against L.
infantum. Based on these findings, further modifications of the
R4 position were discontinued for now.
Next, analogues were prepared with modifications on the
heteroaromatic ring on R5 (Table 3), aiming for lower toxicity.
Moving away from the pyrazoles, instead 1,2,3-triazoles were
introduced by utilizing click reactions on acetylene substituted
hexahydrophthalazinone 43. Having small aliphatic substituents
on the 1,2,3-triazole (44–47) resulted in four compounds with
activities around 5.7 (pIC50), however large differences in MRC-5
toxicity were observed. While methylcyclopropyl 44 and
butyronitrile (47) showed some cytotoxicity against MRC-5 cells
(pIC50 =5.0 and 4.7), methylcyclobutyl (45), cyclopentyl (46)
showed virtually no cytotoxicity with pIC50 values of 4.3 and
<4.2 respectively, resulting in high SI’s of 25 and >31.
Attempts to introduce some polar side chains, by installing
morpholine moieties (48, 49), resulted in compounds with
moderate activities against L. infantum with pIC50 values of 5.1
and 4.7 respectively, while showing cytotoxicity toward MRC-5
cells at similar concentrations. Installing aromatic moieties, such
as benzyl derivatives 50 and 51, resulted in two compounds
Scheme 3. Synthesis of triazole substituted hexahydrophthalazinones: a) Pd(PPh3)4, TEA, TMS-acetylene, 100 °C, 1 h, 93 %, b) KOH, MeOH, RT, 86 %, 16 h, c)
NaN3, MeOH/H2O (8 : 1), 80 °C, 16 h, d) R1  N3, CuSO4.5 H2O, l-ascorbate, MeOH/H2O (8 : 1), RT, 16 h, 34–59 %.
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with activities around 5.4 (pIC50) and no observable toxicity
against MRC-5 cells (pIC50<4.2). While 1,2,3-triazoles showed
substantially lower cytotoxicity than their pyrazole counterparts,
their antiparasitic activities are also lower. The cyclopentyl
substituted triazole, NPD-3189 (46) does however show some
promise with a pIC50 of 5.7 and no toxicity.
Table 1. Phenotypic activity of various N-isopropyl phthalazinones and dihydropyridazinone against intracellular amastigotes of Leishmania infantum and
against MRC-5 cell growth.





A 5.8 4.6 16
21 A 5.1 4.6 3
22 A 6.3 5.1 16
23 A 6.3 5.6 5
24 A 5.1 4.5 4
25 A 5.2 <4.2 >10
26 B 4.5 4.5 1
27 B 4.5 4.5 1
28 C 6.0 4.9 13
29 C 5.7 4.6 13
30 C 6.3 5.4 8
31 D 5.6 5.2 3
32 D 6.0 5.0 10
[a] All reported values are within a standard deviation of �0.2. [b] Selectivity index: IC50(L. inf)/IC50(MRC-5).
Full Papers
223ChemMedChem 2020, 15, 219 – 227 www.chemmedchem.org © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Freitag, 17.01.2020



























































Starting from the screening hit NPD-2942 (6) a series of close
analogues has been prepared to investigate SAR around the
hexahydrophthalazinone scaffold. Variations of the core scaffold
shows that removal of the cyclohexane moiety leads to
compounds with decreased activity (pIC50s around 4.5), mod-
ification of the cyclohexane to a cyclohexene or phenyl moiety
is tolerated, although this generally does not improve potency.
Introduction of several heteroaromatic rings on R3 revealed that
an unsubstituted 2,3-pyrazole on the hexahydrophthalazinone
scaffold (22, NPD-1289) is the most promising analogue of this
series with a pIC50 value of 6.3 and a 16-fold selectivity over
toxicity for MRC-5 cells. Close analogue 30 shows a similar
potency, however is less promising with a relative high
cytotoxicity (pIC50 value =5.4, SI=8). Modifications of the
isopropyl moiety (37–41) led to compounds with high cytotox-
icity toward MRC-5 cells and this position was not further
investigated. Replacing the unsubstituted 2,3-pyrazole with
1,2,3-triazoles (44–51) yielded a set of compounds with lower
activity against L. infantum, although higher selectivity over
MRC-5 cells was achieved with methylcyclobutyl 45 (SI=25)
and cyclopentyl 46 (SI>31). Overall, the current series shows
the promise of the hexahydrophthalazinone scaffold. This new
chemical class shows sub-micromolar anti-leishmanial activity




Leishmania infantum cellular assay: L. infantum MHOM/MA(BE)/67
amastigotes were collected from the spleen of an infected donor
hamster and used to infect primary peritoneal mouse macrophages.
To determine in vitro anti-leishmanial activity, 3 × 104 macrophages
were seeded in each well of a 96-well plate. After 2 d of outgrowth,
5 × 105 amastigotes/well were added and incubated for 2 h at 37 °C.
Solutions with or without test compound were subsequently
added, and the plates were further incubated for 5 d at 37 °C and
Table 2. Phenotypic activity of hexahydrophthalazinones with various N-





37 4.2 5.5 0.05
38 5.9 5.6 2
39 4.4 5.0 0.25
40 5.4 5.6 0.63
41 5.4 6.1 0.20
[a] All reported values are within a standard deviation of �0.2. [b]
Selectivity index: IC50(L. inf)/IC50(MRC-5).
Table 3. Phenotypic activity against intracellular amastigotes of Leishma-





44 5.7 5.0 5
45 5.7 4.3 25
46 5.7 <4.2 >31
47 5.6 4.7 8
48 5.1 4.7 3
49 4.5 4.5 1
50 5.2 <4.2 >10
51 5.5 <4.2 >20
[a] All reported values are within a standard deviation of �0.2. [b]
Selectivity index: IC50(L. inf)/IC50(MRC-5).
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5 % CO2 . Parasite burdens (mean number of amastigotes/macro-
phage) were microscopically assessed on 500 cells after Giemsa
staining of the test plates and expressed as a percentage of the
blank controls without test compound. In the case of observed
toxicity to the macrophages, the lowest concentration was
recorded at which the toxicity was observed, and this was used as a
qualitative phenotypic assessment.[17] As a positive control Miltefo-
sine was used.
MRC-5 cytotoxicity cellular assay: MRC-5 SV2 cells, originally from a
human diploid lung cell line, were cultivated in MEM, supple-
mented with L-glutamine (20 mM), 16.5 mM sodium hydrogen
carbonate and 5 % FCS. For the assay, 104 cells/well were seeded
onto the test plates containing the pre-diluted sample and
incubated at 37 °C and 5 % CO2 for 72 h. Cell viability was assessed
fluorimetrically 4 h after addition of 10 μg/mL resazurin (excitation
550 nm, emission 590 nm). The results are expressed as percentage
reduction in cell viability compared to untreated controls. Tamox-
ifen was used as a positive control in this experiment.
Chemistry
Chemicals and reagents were obtained from commercial suppliers
and were used without further purification. Anhydrous DMF, THF
and CH2Cl2 were obtained by passing them through an activated
alumina column prior to use. Microwave reactions were executed
using a Biotage® Initiator microwave system. 1H NMR spectra were
recorded on a Bruker Avance 250 (250 MHz), Bruker Avance 400
(400 MHz), Bruker Avance 500 (500 MHz) or Bruker 600 Avance
(600 MHz) spectrometer. Data are reported as follows: chemical
shift, integration, multiplicity (s= singlet, d =doublet, dd= double
doublet, t= triplet, dt= double triplet, q=quartet, p= pentet, h=
heptet, bs= broad singlet, m= multiplet), and coupling constants
(Hz). Chemical shifts are reported in ppm with the natural
abundance of deuterium in the solvent as the internal reference
(CDCl3: δ 7.26, (CD3)2SO: δ 2.50).
13C NMR spectra were recorded on
a Bruker Avance 500 (126 MHz) or Bruker Avance 600 (150 MHz).
Chemical shifts are reported in ppm with the solvent resonance
resulting from incomplete deuteration as the internal reference
(CDCl3: δ 77.16 or (CD3)2SO: δ 39.52). Systematic names for
molecules according to IUPAC rules were generated using the
Chemdraw AutoName program. LC  MS data was gathered using a
Shimadzu HPLC/MS workstation with a LC-20AD pump system,
SPD  M20 A diode array detection, and a LCMS-2010 EV mass
spectrometer. The column used is an Xbridge C18 5 μm column
(100 mm × 4.6 mm). Solvents used were the following: solvent
B=MeCN, 0.1 % formic acid; solvent A =water, 0.1 % formic acid.
The analysis was conducted using a flow rate of 1.0 mL/min, start
5 % B, linear gradient to 90 % B in 4.5 min, then 1.5 min at 90 % B,
linear gradient to 5 % B in 0.5 min and then 1.5 min at 5 % B, total
run time of 8 min. All reported compounds have purities >95 %,
measured at 254 nm, unless otherwise mentioned. All HRMS spectra
were recorded on a Bruker microTOF mass spectrometer using ESI
in positive-ion mode. Column purifications were either carried out
automatically using Biotage equipment or manually, using 60–
200 mesh silica. TLC analyses were performed with Merck F254
alumina silica plates using UV visualization. All reactions were done
under N2 atmosphere, unless specifically mentioned.
Syntheses
(E)-4-(3-Bromo-4-methoxyphenyl)-4-oxobut-2-enoic acid (8): To
an ice-cooled mixture of 1-bromo-2-methoxybenzene (6)(65 mL,
0.52 mol) and furan-2,5-dione (77 g, 0.78 mol) in CH2Cl2 (465 mL)
was added AlCl3 (84 g, 0.63 mol). The reaction mixture was stirred
at RT overnight. The orange suspension was quenched in 3 M aq.
HCl (1.5 L) and extracted using EtOAc (4 × 1 L). The combined
organic layers were dried over Na2SO4, filtered and concentrated to
obtain a dark yellow solid. Trituration with Et2O provided the
product as a light yellow solid (97.5 g, 66 %). 1H NMR (500 MHz,
CDCl3): δ 7.89 (d, J= 2.2 Hz, 1H), 7.69 (dd, J= 8.7, 2.2 Hz, 1H), 7.53
(d, J=15.4 Hz, 1H), 6.74 (d, J=8.7 Hz, 1H), 6.51 (d, J=15.4 Hz, 1H),
3.69 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ 187.2, 167.1, 166.7,
160.2, 133.8, 133.0, 131.3, 130.6, 112.9, 111.8, 57.3. LC–MS (ESI) m/z
found: 285 [M+H]+; retention time: 4.09 minutes. HRMS (ESI): m/z:
[M+H]+ calcd. for C11H10BrO4 284.9757, found 284.9763.
(1R,2S)-2-(3-Bromo-4-methoxybenzoyl)cyclohexanecarboxylic
acid (9): cis-hexahydroisobenzofuran-1,3-dione (17.3 g, 112 mmol)
was added to a round bottom flask, followed by 1-bromo-2-
methoxybenzene (6) (20 g, 107 mmol) and CH2Cl2 ( 250 mL). The
mixture was stirred and cooled with an ice-bath. Aluminum
trichloride (17.1 g, 128 mmol) was added in small portions over
approximately 5 min, after which the ice-bath was removed and
the mixture stirred for 16 h, by then the mixture was a deep red
solution. The mixture was quenched in a mixture of ice and
concentrated hydrochloric acid (3 : 1) after which a white solid
precipitated. Solids were filtered off, washed with water (3 × 50 mL)
and dried in vacuo to yield 24 g (63 mmol, 58 %) of the title
compound. 1H-NMR: (500 MHz, DMSO-d6) δ 12.05 (s, 1H), 8.04 (d,
8.6 Hz, 1H), 7.94 (d, 8.6 Hz, 1H), 7.21 (d, J=8.6 Hz, 1H), 3.93 (s, 3H),
3.39 (s, 1H), 2.73–2.58 (m, 1H), 2.03 (q, J=9.5 Hz, 1H), 1.93–1.78 (m,
2H), 1.78–1.67 (m, 1H), 1.67–1.56 (m, 1H), 1.44–1.23 (m, 2H), 1.24–
1.10 (m, 1H). LC–MS (ESI) m/z found: 341 [M+H]+; retention time:
4.43 minutes, purity: 85 %. HRMS-ESI [M+H]+ calculated for
C15H18BrO4: 341.0383, found 341.0392.
trans-6-(3-Bromo-4-methoxybenzoyl)cyclohex-3-ene-1-carboxylic
acid (11): A mixture of keto-acid 8 (70.0 g, 221 mmol) and buta-1,3-
diene in THF (~ 13 % w/w, 150 mL, 300 mmol) was divided over 8
microwave vials. Each vial was stirred under microwave irradiation
at 140 °C for 30 min (the internal pressure reached ~ 10 bar). The
reaction mixtures were pooled and concentrated in vacuo to obtain
the crude product. Trituration with toluene provided the product as
a white solid (72.4 g, 97 %). 1H NMR (500 MHz, DMSO-d6): δ 12.30 (s,
1H), 8.16 (s, 1H), 8.07 (d, J= 8.7 Hz, 1H), 7.23 (d, J=8.5 Hz, 1H), 5.79–
5.66 (m, 2H), 3.95 (s, 3H), 3.83–3.72 (m, 1H), 2.92–2.75 (m, 1H), 2.54–
2.10 (m, 3H), 1.93–1.79 (m, 1H). 13C NMR (126 MHz, DMSO-d6): δ
200.8, 176.4, 159.61 133.4, 130.6, 130.3, 125.8, 125.7, 112.8, 111.6,
57.2, 42.2, 41.6, 29.4, 28.4. LC–MS (ESI) m/z found: 339 [M+H]+;
retention time: 4.53 minutes. HRMS (ESI): m/z: [M+ H]+ calcd. for
C15H16BrO4 339.0226, found 339.0213.
(4aS,8aR)-4-(3-Bromo-4-methoxyphenyl)-4a,5,6,7,8,8a-hexahy-
drophthalazin-1(2H)-one (13): Keto-acid 10 (13.0 g, 38.1 mmol) was
charged to a round bottom flask followed by ethanol (150 mL). This
suspension was stirred and hydrazine hydrate (50–60 % (20 mL,
381 mmol) was added in portions. The mixture was heated at 60 °C
for 16 h after which it was allowed the cool to RT while stirring.
White precipitation was visible and 50 mL of water was added,
increasing precipitation. Solids were filtered off and dried in vacuo
to yield 11.4 gram (33.8 mmol, 89 %) of the title compound as a
white solid. 1H-NMR: (500 MHz, DMSO-d6) δ 10.89 (s, 1H), 7.97 (d,
J= 2.1 Hz, 1H), 7.76 (dd, J= 8.7, 2.2 Hz, 1H), 7.15 (d, J= 8.8 Hz, 1H),
3.88 (s, 3H), 3.29–3.20 (m, 1H), 2.71 (s, 1H), 2.28 (d, J=12.5 Hz, 1H),
1.67 (d, J=12.6 Hz, 1H), 1.56–1.47 (m, 2H), 1.45–1.33 (m, 2H), 1.30–
1.16 (m, 2H). LC–MS (ESI) m/z found: 337 [M+H]+; retention time:




13 (5.0 g, 14.8 mmol) was dissolved in DMF (100 mL) and sodium
hydride (60 % in mineral oil) (652 mg, 16.3 mmol) was added. The
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mixture was stirred for 15 min after which 2-bromopropane
(1.67 mL, 17.8 mmol) was added and the mixture was stirred for
16 h at 60 °C. The reaction was quenched pouring the mixture in
water (250 mL) and the aqueous layer was extracted with MTBE
(250 mL). The organic layer was washed with sat. aqueous NaHCO3
(2x 250 mL) and brine (250 mL) after which the organic layer was
dried over Na2SO4. The solids were filtered off and volatiles were
evaporated in vacuo after which the remaining crude was purified
over SiO2 using a gradient of 10 % EtOAc in heptane toward 50 %
EtOAc in heptane yielding 4.6 g (12.1 mmol, 82 %) of the title
compound as a white solid. 1H-NMR: (500 MHz, CDCl3) δ 7.98 (s, 1H),
7.69 (d, J=8.6 Hz, 1H), 6.90 (d, 1H), 5.03 (hept, J=6.4 Hz, 1H), 3.03–
2.93 (m, 1H), 2.63 (s, 1H), 2.60–2.47 (m, 1H), 1.84–1.72 (m, 1H), 1.68–
1.56 (m, 2H), 1.40–1.30 (m, 3H), 1.29 (d, J=6.6 Hz, 3H), 1.21 (d, J=
6.7 Hz, 3H). 13C-NMR: (126 MHz, CDCl3) δ 166.45, 156.68, 151.24,
130.75, 129.19, 126.15, 112.06, 111.47, 56.36, 46.40, 36.69, 35.48,
26.90, 25.67, 24.28, 23.98, 20.65, 20.18. LC–MS (ESI) m/z found: 379
[M+H]+; retention time: 5.51 minutes. HRMS-ESI [M+H]+ calcu-
lated for C18H24BrN2O2: 379.1016, found 379.1009.
2-Isopropyl-4-(4-methoxy-3-(1H-pyrazol-4-yl)phenyl)-
4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one (22): Phthalazinone
17 (100 mg, 0.26 mmol) and (1H-pyrazol-4-yl)boronic acid (35 mg,
0.32 mmol) were added to a microwave tube with a stirring bean,
subsequently DME (3 mL) and 1 M sodium carbonate (0.9 mL,
0.9 mmol) were added and the mixture was degassed for 5 minutes
with N2. After addition of PdCl2(dppf).CH2Cl2 (20 mg, 0.026 mmol)
the mixture was degassed for another 2 min and the vessel was
sealed and heated for 1 h at 120 °C. The mixture was diluted with
EtOAc (25 mL), filtered over Celite and the organic layer was
washed with water (2 × 25 mL) and brine (25 mL). The organic layer
was dried over Na2SO4, solids were filtered off and the residue was
concentrated in vacuo. Remaining crude was purified over SiO2
using a gradient of 50 % heptanes in EtOAc toward 5 % MeOH in
EtOAc to yield the 18 mg (0.05 mmol, 19 %) of title compound as an
off-white solid. 1H-NMR: (500 MHz, CDCl3) δ 8.08 (s, 2H), 8.04 (d, J=
2.3 Hz, 1H), 7.64 (dd, J= 8.6, 2.3 Hz, 1H), 6.99 (d, J=8.6 Hz, 1H), 5.08
(hept, J=6.6 Hz, 1H), 3.95 (s, 3H), 3.13–3.03 (m, 1H), 2.72–2.65 (m,
1H), 2.61–2.52 (m, 1H), 1.85–1.76 (m, 1H), 1.73–1.60 (m, 2H), 1.49–
1.35 (m, 4H), 1.33 (d, J=6.6 Hz, 3H), 1.25 (d, J=6.6 Hz, 3H). 13C-NMR:
(126 MHz, CDCl3) δ 166.60, 156.95, 152.67, 133.16, 127.93, 125.30,
125.22, 121.55, 117.70, 110.93, 55.65, 46.40, 36.76, 35.61, 25.76,
24.44, 24.06, 22.06, 20.69, 20.24. LC–MS (ESI) m/z found: 367 [M+
H]+; retention time: 4.55 minutes. HRMS-ESI [M+H]+ calculated for
C21H27N4O2: 367.2129, found 367.2116.
(4aS,8aR)-4-(3-Bromo-4-methoxyphenyl)-2-(cyclobutylmethyl)-
4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one (33): Phthalazinone
13 (450 mg, 1.33 mmol) was dissolved in DMF (10 mL) and sodium
hydride (60 % in mineral oil) (59 mg, 1.5 mmol) was added. The
mixture was stirred for 15 min after which (bromomethyl)cyclo-
butane (0.18 mL, 1.6 mmol) was added and the mixture was stirred
for another 16 h. The reaction was quenched pouring the mixture
in water (50 mL) and the aqueous layer was extracted with MTBE
(50 mL). The organic layer was washed with sat. aqueous NaHCO3
(2x 50 mL) and brine (50 mL) after which the organic layer was
dried over Na2SO4. The solids were filtered off and volatiles were
evaporated in vacuo after which the remaining crude was purified
over SiO2 using a gradient of 10 % EtOAc in heptane toward 70 %
EtOAc in heptane yielding 430 mg (1.06 mmol, 79 %) of the title
compound as a white solid. 1H-NMR: (500 MHz, CDCl3) δ 7.97 (d, J=
2.1 Hz, 1H), 7.66 (dd, J= 8.6, 2.1 Hz, 1H), 6.90 (d, J=8.7 Hz, 1H), 4.13
(dd, J=13.2, 7.7 Hz, 1H), 3.93 (s, 3H), 3.65 (dd, J=13.2, 7.1 Hz, 1H),
3.05–2.95 (m, 1H), 2.75 (h, J=7.8 Hz, 1H), 2.70–2.64 (m, 1H), 2.59–
2.49 (m, 1H), 2.07–1.97 (m, 2H), 1.93–1.76 (m, 5H), 1.69–1.59 (m, 3H),
1.45–1.23 (m, 5H). 13C-NMR: (126 MHz, CDCl3) δ 167.17, 156.74,
151.27, 130.83, 128.89, 126.20, 112.11, 111.47, 56.37, 53.30, 36.40,
35.96, 26.12, 26.09, 25.71, 24.40, 23.95, 22.00, 18.46. LC–MS (ESI) m/z
found: 405 [M+ H]+; retention time: 5.91 minutes. HRMS-ESI [M+
H]+ calculated for C20H26BrN2O2: 405.1172, found 405.1165.
(4aS,8aR)-2-(Cyclobutylmethyl)-4-(4-methoxy-3-(1H-pyrazol-4-yl)
phenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one (38): Phtha-
lazinone 33 (150 mg, 0.37 mmol) and (1H-pyrazol-4-yl)boronic acid
(62 mg, 0.56 mmol) were added to a microwave tube with a stirring
bean, subsequently DME (4 mL) and 1 M sodium carbonate (2 mL,
2.0 mmol) were added and the mixture was degassed for 5 min
with N2. After addition of PdCl2(dppf).CH2Cl2 (30 mg, 0.037 mmol)
the mixture was degassed for another 2 minutes and the vessel was
sealed and heated for 1 h at 120 °C. The mixture was diluted with
EtOAc (25 mL), filtered over Celite and the organic layer was
washed with water (2 × 25 mL) and brine (25 mL). The organic layer
was dried over Na2SO4, solids were filtered off and the residue was
concentrated in vacuo. Remaining crude was purified over SiO2
using a gradient of 50 % heptanes in EtOAc toward 5 % MeOH in
EtOAc to yield 37 mg (0.09 mmol, 25 %) of the title compound as an
off-white solid. 1H-NMR: (500 MHz, CDCl3) δ 8.09 (s, 2H), 8.00 (d, J=
1.8 Hz, 1H), 7.59 (dd, J= 8.6, 2.0 Hz, 1H), 6.97 (d, J=8.7 Hz, 1H), 4.17
(dd, J=13.2, 7.6 Hz, 1H), 3.94 (s, 3H), 3.68 (dd, J=13.2, 7.1 Hz, 1H),
3.14–3.03 (m, 1H), 2.82–2.68 (m, 2H), 2.61–2.51 (m, 1H), 2.12–1.97
(m, 2H), 1.94–1.76 (m, 5H), 1.73–1.59 (m, 2H), 1.50–1.29 (m, 4H). 13C-
NMR: (126 MHz, CDCl3) δ 167.35, 157.02, 152.87, 133.38, 127.59,
125.35, 125.22, 121.77, 117.58, 110.94, 105.69, 55.63, 53.25, 36.47,
36.12, 34.86, 26.20, 25.78, 24.55, 24.02, 22.08, 18.52. LC–MS (ESI) m/z
found: 393 [M+ H]+; retention time: 4.83 minutes. HRMS-ESI [M+
H]+ calculated for C23H28N4O2: 393.2285, found 393.2276.
(4aS,8aR)-2-Isopropyl-4-(4-methoxy-3-((trimethylsilyl)ethynyl)
phenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one (42): Phtha-
lazinone 13 (2.0 g, 5.3 mmol) was added to a microwave tube and
TEA (12 mL) was added. The mixture was degassed with N2 for
5 min after which Tetrakis (0.61 g, 0.53 mmol) and CuI (0.1 g,
0.53 mmol) were added. The tube was heated in the microwave at
100 °C for 1 h, after which the mixture was allowed to cool to RT,
diluted with MTBE (25 mL) and filtered over Celite. The organic
layer was washed with saturated aqueous NaHCO3 (2 × 25 mL) and
brine (25 mL), after which it was dried over Na2SO4 and solids were
filtered off. The remaining black crude was concentrated in vacuo
and purified over SiO2 using a gradient of heptane toward 25 %
EtOAc in heptane yielding 1.95 g (4.9 mmol, 93 %) of the title
compound as a white solid. 1H-NMR: (500 MHz, CDCl3) δ 7.83–7.76
(m, 2H), 6.89 (d, J=8.7 Hz, 1H), 5.05 (hept, J= 6.6 Hz, 1H), 3.92 (s,
3H), 3.07–2.99 (m, 1H), 2.63 (s, 1H), 2.55 (d, J= 9.8 Hz, 1H), 1.83–1.75
(m, 1H), 1.68–1.60 (m, 2H), 1.58 (s, 2H), 1.41–1.32 (m, 2H), 1.31 (d,
J= 6.6 Hz, 3H), 1.23 (d, J=6.7 Hz, 3H), 0.29 (s, 8H). LC–MS (ESI) m/z
found: 397 [M+H]+; retention time: 6.09 minutes.
(4aS,8aR)-4-(3-Ethynyl-4-methoxyphenyl)-2-isopropyl-
4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one (43): Phthalazinone
42 (2.0 g, 5.0 mmol) was charged to a round bottom flask, followed
by MeOH (50 mL) and 2.5 M aqueous potassium hydroxide. The
mixture was stirred overnight at RT for 16 h, after which the
aqueous layer was extracted with EtOAc (50 mL). The organic layer
was washed with brine (50 mL) and dried over Na2SO4 after which
the solids were filtered off. Volatiles were removed in vacuo, after
which the remaining crude was purified over SiO2 using a gradient
of 10 % EtOAc in heptanes toward 70 % EtOAc in heptanes yielding
1.4 g (5.0 mmol, 86 %) of the title compound as a white solid. 1H-
NMR: (500 MHz, CDCl3) δ 7.87 (d, J=2.3 Hz, 1H), 7.81 (dd, J=8.8,
2.3 Hz, 1H), 6.93 (d, J=8.8 Hz, 1H), 5.05 (hept, J= 6.6 Hz, 1H), 3.95 (s,
3H), 3.35 (s, 1H), 3.07–2.97 (m, 1H), 2.67–2.62 (m, 1H), 2.59–2.50 (m,
1H), 1.84–1.76 (m, 1H), 1.68–1.60 (m, 2H), 1.47–1.32 (m, 4H), 1.30 (d,
J= 6.6 Hz, 3H), 1.23 (d, J= 6.7 Hz, 3H). 13C-NMR: (126 MHz, CDCl3) δ
166.47, 161.36, 151.60, 131.59, 128.01, 127.84, 111.30, 110.66, 81.51,
79.74, 56.11, 46.36, 36.70, 35.47, 25.69, 24.28, 24.01, 22.00, 20.65,
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20.18. LC–MS (ESI) m/z found: 325 [M+H]+; retention time: 5.12




1(2H)-one (44): (azidomethyl)cyclopropane was freshly prepared by
refluxing (bromomethyl)cyclopropane (0.49 g, 3.6 mmol) and so-
dium azide (0.47 g, 7,2 mmol) in 4 mL MeOH and 0.5 mL H2O for
16 h. To a tube 1 mL of the azide solution (0.8 M) was added
followed by alkyne 43 (50 mg, 0.15 mmol), (+)-sodium l-ascorbate
(3 mg, 0.015 mmol) and CuSO4.5 H2O (4 mg, 0.015 mmol), after
which the tube was sealed. The reaction was stirred overnight at
room temperature after which the reaction was quenched in 1 M
aqueous Na2CO3 (25 mL) and extracted with EtOAc (2 × 25 mL). The
organic layer was washed with 1 M aqueous Na2CO3 (2 × 25 mL) and
brine (25 mL), dried over Na2SO4 and filtered off. The remaining
residue was concentrated in vacuo and purified over SiO2 using a
gradient of 70 % heptanes in EtOAc toward 30 % heptanes in EtOAc
yielding 27 mg (0.06 mmol, 43 %) of the title compound as a white
solid. 1H-NMR: (500 MHz, CDCl3) δ 8.66 (d, J=2.3 Hz, 1H), 8.13 (s,
1H), 7.92 (dd, J= 8.8, 2.4 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 5.06 (hept,
J= 6.7 Hz, 1H), 4.28 (d, J=7.2 Hz, 2H), 3.99 (s, 3H), 3.28–3.18 (m, 1H),
2.70–2.64 (m, 1H), 2.59–2.50 (m, 1H), 1.81–1.57 (m, 5H), 1.49–1.33
(m, 5H), 1.32 (d, J= 6.6 Hz, 3H), 1.25 (d, J=6.7 Hz, 3H), 0.75–0.68 (m,
2H), 0.52–0.44 (m, 2H). 13C-NMR: (126 MHz, CDCl3) δ 166.70, 156.47,
152.97, 142.69, 138.93, 133.38, 128.32, 126.80, 125.27, 122.79,
121.77, 119.38, 111.22, 55.70, 54.95, 46.34, 36.80, 35.38, 25.64, 24.27,
24.01, 22.07, 20.66, 20.21, 11.31, 4.24. LC–MS (ESI) m/z found: 422
[M+H]+; retention time: 5.12 minutes. HRMS-ESI [M+H]+ calcu-
lated for C24H31N5O2: 422.2551, found 422.2543.
Author Contributions
M.S. and E.d.H. contributed to the synthesis of the molecules,
A.M., G.C. and L.M. were involved with the parasitological
screenings, M.S., L.M., G.S, and R.L. were involved in the design
of the molecules and experiments. L.M, G.C., G.S, I.J.Pd.E., and
R.L. obtained the necessary funding. M.S., G.S., and R.L.
contributed to the writing of this manuscript. All authors have






MTBE methyl tert-butyl ether
VL visceral leishmaniasis
Acknowledgements
The authors thank H. Custers and A. van der Stolpe for their
technical assistance. The PDE4NPD project was funded by the
European Union under the FP-7-Health program, project ID:
602666.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: antiprotozoal agents · leishmaniasis ·
phenylphthalazinones · structure-activity relationships ·
leishmania infantum
[1] WHO, WHO fact sheet on Leishmaniasis. https://www.who.int/en/news-
room/fact-sheets/detail/leishmaniasis, Vol. 2018, 2018.
[2] F. Chappuis, S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W. Peeling, J. Alvar,
M. Boelaert, Nat. Rev. Microbiol. 2007, 5, 873–882.
[3] R. Reithinger, J.-C. Dujardin, H. Louzir, C. Pirmez, B. Alexander, S.
Brooker, The Lancet Infectious Diseases 2007, 7, 581–596.
[4] a) E. Moore, D. O. Flaherty, H. Heuvelmans, J. Seaman, H. Veeken, S.
d. Wit, R. N. Davidson, Bull. W. H. O. 2001, 79, 388–393; b) WHO, World
Health Organisation Technical Report Series 2012, 949.
[5] B. L. Herwaldt, J. D. Berman, The American Journal of Tropical Medicine
and Hygiene 1992, 46, 296–306.
[6] F. Frézard, C. Demicheli, R. Ribeiro, Molecules 2009, 14, 2317.
[7] S. L. Croft, S. Sundar, A. H. Fairlamb, Clin. Microbiol. Rev. 2006, 19, 111–
126.
[8] S. Sundar, J. Chakravarty, Journal of Global Infectious Diseases 2010, 2,
159–166.
[9] S. K. Bhattacharya, P. K. Sinha, S. Sundar, C. P. Thakur, T. K. Jha, K.
Pandey, V. R. Das, N. Kumar, C. Lal, N. Verma, V. P. Singh, A. Ranjan, R. B.
Verma, G. Anders, H. Sindermann, N. K. Ganguly, The Journal of
Infectious Diseases 2007, 196, 591–598.
[10] a) V. Bhandari, A. Kulshrestha, D. K. Deep, O. Stark, V. K. Prajapati, V.
Ramesh, S. Sundar, G. Schonian, J. C. Dujardin, P. Salotra, PLoS Neglected
Trop. Dis. 2012, 6, e1657; b) K. Pandey, S. Pun, B. Pandey, Indian J. Med.
Microbiol. 2012, 30, 227–229; c) R. Obonaga, O. L. Fernández, L.
Valderrama, L. C. Rubiano, M. D. M. Castro, M. C. Barrera, M. A. Gomez,
N. Gore Saravia, Antimicrob. Agents Chemother. 2014, 58, 144–152.
[11] a) R. N. Davidson, M. den Boer, K. Ritmeijer, Trans. R. Soc. Trop. Med. Hyg.
2009, 103, 653–660; b) A. Ben Salah, N. Ben Messaoud, E. Guedri, A.
Zaatour, N. Ben Alaya, J. Bettaieb, A. Gharbi, N. Belhadj Hamida, A.
Boukthir, S. Chlif, K. Abdelhamid, Z. El Ahmadi, H. Louzir, M. Mokni, G.
Morizot, P. Buffet, P. L. Smith, K. M. Kopydlowski, M. Kreishman-Deitrick,
K. S. Smith, C. J. Nielsen, D. R. Ullman, J. A. Norwood, G. D. Thorne, W. F.
McCarthy, R. C. Adams, R. M. Rice, D. Tang, J. Berman, J. Ransom, A. J.
Magill, M. Grogl, N. Engl. J. Med. 2013, 368, 524–532.
[12] S. Hendrickx, A. Mondelaers, E. Eberhardt, P. Delputte, P. Cos, L. Maes,
Antimicrob. Agents Chemother. 2015, 59, 4714.
[13] C. P. Thakur, T. P. Kanyok, A. K. Pandey, G. P. Sinha, A. E. Zaniewski, H. H.
Houlihan, P. Olliaro, Trans. R. Soc. Trop. Med. Hyg. 2000, 94, 429–431.
[14] H. Goto, J. A. L. Lindoso, Expert Rev. Anti-Infect. Ther. 2010, 8, 419–433.
[15] E. de Heuvel, A. K. Singh, E. Edink, T. van der Meer, M. van der Woude, P.
Sadek, M. P. Krell-Jørgensen, T. van den Bergh, J. Veerman, G. Caljon,
T. D. Kalejaiye, M. Wijtmans, L. Maes, H. P. de Koning, G. Jan Sterk, M.
Siderius, I. J. P. de Esch, D. G. Brown, R. Leurs, Bioorg. Med. Chem. 2019,
27, 15.
[16] S. Nijmeijer, H. Engelhardt, S. Schultes, A. C. van de Stolpe, V. Lusink, C.
de Graaf, M. Wijtmans, E. E. J. Haaksma, I. J. P. de Esch, K. Stachurski,
H. F. Vischer, R. Leurs, Br. J. Pharmacol. 2013, 170, 12.
[17] A. R. Blaazer, K. M. Orrling, A. Shanmugham, C. Jansen, L. Maes, E. Edink,
G. J. Sterk, M. Siderius, P. England, D. Bailey, I. J. P. de Esch, R. Leurs, J.
Biomol. Screening 2014, 20, 10.
Manuscript received: September 20, 2019
Revised manuscript received: November 17, 2019
Accepted manuscript online: November 22, 2019
Version of record online: December 9, 2019
Full Papers
227ChemMedChem 2020, 15, 219 – 227 www.chemmedchem.org © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Freitag, 17.01.2020
2002 / 153303 [S. 227/227] 1
